Table 4.
Sensitivity Analyses
| Reduction in Prevalence | % Reduction in Prevalence | Reduction in direct and indirect costs (USD billions) | % Reduction in direct and indirect costs | |
|---|---|---|---|---|
| Model 1: Coronary Heart Disease | ||||
| Central Estimate | 279,000 | 1.8% | 3.2 | 1.8% |
| +20% : US population in the noise exposed group | 334,000 | 2.2% | 3.8 | 2.2% |
| −20% : US population in the noise exposed group | 224,000 | 1.5% | 2.5 | 1.5% |
| +20% : risk ratio associated with exposed group | 334,000 | 2.2% | 3.8 | 2.2% |
| −20% : risk ratio associated with exposed group | 224,000 | 1.5% | 2.5 | 1.5% |
| +20% : direct and indirect costs | 279,000 | 1.8% | 3.9 | 1.8% |
| −20% : direct and indirect costs | 279,000 | 1.8% | 2.6 | 1.8% |
| Model 2: Hypertension | ||||
| Central Estimate | 1.2 million | 1.4% | 0.7 | 1.4% |
| +20% : US population in the noise exposed group | 1.4 million | 1.7% | 0.9 | 1.7% |
| −20% : US population in the noise exposed group | 967,000 | 1.2% | 0.6 | 1.2% |
| +20% : risk ratio associated with exposed group | 1.4 million | 1.7% | 0.9 | 1.7% |
| −20% : risk ratio associated with exposed group | 967,000 | 1.2% | 0.6 | 1.2% |
| +20% : direct and indirect costs | 1.2 million | 1.4% | 0.9 | 1.4% |
| −20% : direct and indirect costs | 1.2 million | 1.4% | 0.6 | 1.4% |